mRNA Cancer Vaccines: Why 2026 Readouts Matter for Oncology A 49% lower risk of melanoma coming back after surgery sounds like hype copy, but it’s a real number from Moderna and Merck’s individualized mRNA vaccine plus Keytruda combo at 5‑year follow‑up. That’s what mRNA cancer vaccines quietly did in a Phase 2b trial while Reddit argued about “curing cancer.” 2026 is when this stops being a handful of glamorous proofs‑of‑concept and becomes a practical question: can we actually run this at scale, pay for it, and plug it into messy real‑world oncology?

49% fewer melanoma recurrences at 5 years—Moderna/Merck’s mRNA vaccine + Keytruda worked. 2026 readouts will tell if this can scale, be paid for, and actually reach patients. #Moderna #Merck #Keytruda

Ivermectin and Fenbendazole for Female Reproductive System: 27 Case Reports (March 2026 Edition) Introduction Cancers of the female reproductive system, including ovarian, endometrial (uterine), an...

#case #studies #cervical #cancer #keytruda #ovarian #cancer #repurposed #drugs #uterine […]

MSD splits pharma business, hiving off oncology MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

#MSD has said it plans to separate its #cancer and non-cancer #pharma operations as it prepares for the looming loss of #patent protection for $31 billion-plus blockbuster #Keytruda.

pharmaphorum.com/news/msd-spl...

This is big news. As a scientist and ovarian cancer researcher, I know that platinum resistant ovarian cancer is a bear to treat. A major advance in the field of #ovariancancer. Let's keep it up and find more options for these women. #Keytruda #immunotherapy #pembrolizumab

🏆 #Keytruda sigue siendo el fármaco más vendido del mundo.
🔥 Los medicamentos GLP-1 vuelven con fuerza.

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com

#Oncología #GLP1 #Biotecnología #MercadoFarmacéutico #Salud #SaludGlobal #Cáncer #Diabetes #Inmunoterapia #DengYueMedicinasEnHongKong

New Combination Therapy for PD-L1 Positive TNBC Shows Promising Results in Clinical Trial Published in NEJM The combination of Trodelvy and Keytruda could become a new standard for treating patients with PD-L1 positive metastatic triple-negative breast cancer, as per the phase III trial results.

New Combination Therapy for PD-L1 Positive TNBC Shows Promising Results in Clinical Trial Published in NEJM #USA #TNBC #Foster_City #KEYTRUDA #Trodelvy

Ivermectin and Fenbendazole for Female Reproductive System: 25 Case Reports (January 2026) Introduction Cancers of the female reproductive system, including ovarian, endometrial (uterine), and cerv...

#case #studies #cervical #cancer #keytruda #ovarian #cancer #repurposed #drugs #uterine […]

Moderna’s Skin Cancer Vaccine Is Looking Seriously Promising A personalized vaccine cuts melanoma recurrence by half over five years.

#Diseases #Future #News #cancer #vaccine #clinical #trials #immunotherapy #Keytruda #melanoma #Merck

Origin | Interest | Match

Moderna-Merck mRNA Vaccine Slashes Melanoma Recurrence by 49% at 5 Years Moderna and Merck's mRNA vaccine, combined with Keytruda, shows sustained efficacy against high-risk melanoma, reducing ...

#HealthRevolution #Keytruda #combination #therapy #melanoma […]

[Original post on webpronews.com]

Moderna’s cancer therapy mRNA-4157 (V940), combined with Merck’s Keytruda, reduced mortality by 49% in a mid-stage trial, according to the Phase 2b KEYNOTE-942/mRNA-4157-P201 study.

#Moderna #Merck #Keytruda #CancerTherapy #Oncology

10. Love… or launch? - Between a Rocket & a Hard Space Guest, Paul Reichert of Merck Research Labs

#Space #NASA #ISS

My friend Paul Reichert was interviewed last month about Merck's protein crystallization on ISS that developed an ingredient in their cancer drug #Keytruda.

www.buzzsprout.com/2269664/epis...

What happens after you outlive the odds? Don Jackson shares what long-term cancer survivorship looks like. Thank you Don for turning to Smart Patients for support! Read the full story: https://ow.ly/a6Ex50XNeSR

#HeadAndNeckCancer #CancerSurvivorship #Keytruda #CaregiverSupport #PatientCommunity

Innovative Cancer Treatment: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients The combination of PADCEV and Keytruda demonstrates significant improvements in survival rates for patients with muscle-invasive bladder cancer. This marks a potential new standard of care.

Innovative Cancer Treatment: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients #Japan #Tokyo #KEYTRUDA #PADCEV #Bladder_Cancer

TuHURA Biosciences Updates on Key Developments Following Recent Financing TuHURA Biosciences announces significant progress in its Phase 3 trials and financing plans aimed at enhancing cancer treatment options in 2026.

TuHURA Biosciences Updates on Key Developments Following Recent Financing #USA #Tampa,_Florida #Vista #KEYTRUDA #TuHURA_Biosciences

Why Continued Innovation Matters: Keytruda and the "Product Hopping" Myth The FDA recently approved a new version of Keytruda, a cancer immunotherapy medicine that is one of the world’s most successful drugs. Until now, all patients received Keytruda through intravenous…

A recent C4IP blog post examines the #FDA's approval of a new, subcutaneous formulation of #Keytruda.

We explain how this exemplifies the value to #patients of follow-on #innovation and rebut critics who claim the updated formulation is an unnecessary "product hop."

Learn more:

Zydus and Formycon Collaborate for Biosimilar Keytruda in North America Zydus Lifesciences and Formycon have formed a strategic partnership to bring FYB206, a biosimilar of Keytruda, to the U.S. and Canada, enhancing patient access.

Zydus and Formycon Collaborate for Biosimilar Keytruda in North America #India #Ahmedabad #KEYTRUDA #Zydus_Lifesciences #Formycon

Pharmalittle: We're reading about FDA's Prasad defending his plans, a Merck setback in Germany, and more In today's Pharmalittle roundup, we're reading about FDA's Prasad defending his plans, a Merck setback in Germany, and more.

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about FDA’s Prasad defending his plans, a Merck setback in Germany, and more news.. statnews.com/pharmalot/20... #pharma #FDA #Prasad #vaccines #MarkCuban #Merck #Keytruda #generics #patents

Merck suffers a setback over its new Keytruda formulation in Germany In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new subcutaneous formulation of

ICYMI: Merck suffers a setback over its new Keytruda formulation in Germany.. statnews.com/pharmalot/20... #pharma #cancer #Keytruda #Germany #patents #Merck #Halozyme

Merck suffers a setback over its new Keytruda formulation in Germany In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new subcutaneous formulation of

Merck suffers a setback over its new Keytruda formulation in Germany.. statnews.com/pharmalot/20... #pharma #patents #Keytruda #Merck #Germany #Halozyme

Halozyme Secures Preliminary Injunction Against Merck's Keytruda in Germany Amid Patent Dispute Halozyme has obtained a preliminary injunction from a German court against Merck regarding Keytruda SC, citing patent infringement concerns. This ruling halts the drug's distribution in Germany.

Halozyme Secures Preliminary Injunction Against Merck's Keytruda in Germany Amid Patent Dispute #Germany #Halozyme #Munich #KEYTRUDA #Merck

Formycon and MS Pharma Establish Key Partnership for Keytruda® Biosimilar in MENA Region Formycon AG and MS Pharma announce an exclusive licensing agreement for the Keytruda® biosimilar candidate. This partnership aims to enhance cancer treatment accessibility in the MENA region.

Formycon and MS Pharma Establish Key Partnership for Keytruda® Biosimilar in MENA Region #Germany #KEYTRUDA #MS_Pharma #Formycon #Planegg-Martinsried

Antengene's IND Approval in China for ATG-022 Clinical Study: A Step Forward in Cancer Treatment Antengene's ATG-022 receives IND approval in China for a pivotal clinical study. This innovative therapy aims to enhance treatment for specific cancers.

Antengene's IND Approval in China for ATG-022 Clinical Study: A Step Forward in Cancer Treatment #China #Shanghai #Antengene #KEYTRUDA #ATG-022

FDAが筋層浸潤性膀胱がんに対するパドセブ＋キイトルーダの周術期併用療法を承認、EV-303試験でEFS・OSに有意改善 | STELLANEWS.LIFE PfizerとAstellasは、シスプラチン不適格の筋層浸潤性膀胱がん（MIBC）を対象に、パドセブ（エンホルツマブ ベドチン）＋キイトルーダ（ペムブロリズマブ）の周術期併用療法がFDAにより承認されたと発表。第3相EV-303試験でEFSとOSの改善が認められた。

FDA Approves PADCEV + Keytruda for Perioperative Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

🔗 Full article: stellanews.life/technology_c...

#FDA #PADCEV #Keytruda #BladderCancer #Immunotherapy #ADC #EV303 #Astellas #Pfizer #Oncology

KEYTRUDA皮下投与型がEUで承認、がん治療で初の1分投与可能な免疫チェックポイント阻害薬 | STELLANEWS.LIFE メルクのKEYTRUDA（ペムブロリズマブ）皮下投与型が欧州委員会により承認。従来の点滴型に比べ、最短1分での投与が可能となり、がん患者の治療選択肢が拡大。

Keytruda SC approved in the EU — the first checkpoint inhibitor enabling 1-minute subcutaneous dosing.

🔗 Full article: stellanews.life/technology_c...

#Keytruda #MSD #Merck #Pembrolizumab #ImmunoOncology #CheckpointInhibitor #Subcutaneous #CancerTreatment #Oncology #Innovation

【KEYTRUDA皮下投与型がEUで承認】
メルク（MSD）は、ペムブロリズマブ製剤「KEYTRUDA（キイトルーダ）」の皮下投与型（Keytruda SC）が、
欧州連合で成人の全適応に対して承認されたと発表。

#MSD #Merck #Keytruda #キイトルーダ #がん免疫療法 #皮下投与 #欧州承認 #Pembrolizumab #免疫チェックポイント阻害薬 #がん治療

Kelun-Biotech Achieves Key Milestone in Phase III Trial for Lung Cancer Treatment Combining Sac-TMT and KEYTRUDA® Kelun-Biotech's Phase III trial shows promising results for Sac-TMT combined with KEYTRUDA® in treating advanced NSCLC, meeting primary endpoints.

Kelun-Biotech Achieves Key Milestone in Phase III Trial for Lung Cancer Treatment Combining Sac-TMT and KEYTRUDA® #China #Chengdu #Kelun-Biotech #KEYTRUDA #Sac-TMT

TuHURA Biosciences, Inc. Shares Progress on Clinical Trials and Financial Insights for Q3 2025 TuHURA Biosciences has reported its Q3 financial results and provided updates on the Phase 3 trial of IFx-2.0 as a cancer therapy, highlighting key achievements.

TuHURA Biosciences, Inc. Shares Progress on Clinical Trials and Financial Insights for Q3 2025 #United_States #Tampa #KEYTRUDA #TuHURA_Biosciences #IFx-2.0

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của…

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới

🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu 

Trong vòng một thập niên, Keytruda (Pembrolizumab) của…